Regentis Biomaterials Ltd. (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. The approval marks a significant step toward commercializing a treatment for cartilage damage, a condition affecting millions worldwide. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The new manufacturing process eliminates the use of solvents, enhancing environmental and occupational safety. With a 400% increase in yield, Regentis can produce five times more GelrinC from the same manufacturing volume, potentially lowering costs and improving supply reliability. This scalability is critical for meeting demand in Europe and future expansion into the U.S. market, where no off-the-shelf treatment is available for cartilage knee repair.
GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. The implant is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. This cell-free, off-the-shelf approach offers a potential alternative to existing treatments that often require cell harvesting or multiple surgeries.
The company’s focus on orthopedic treatments leverages its Gelrin platform technology, based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue including inflamed cartilage and bone. The European approval for the next-generation manufacturing process is a key enabler for commercial launch, positioning Regentis to capture a share of the large cartilage repair market.
For more information, visit the full press release at https://ibn.fm/Ths4h.
